Point72 Asset Management L.P. Has $4.38 Million Holdings in enGene Holdings Inc. (NASDAQ:ENGN)

Point72 Asset Management L.P. boosted its stake in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) by 1,410.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 663,000 shares of the company's stock after acquiring an additional 619,100 shares during the quarter. Point72 Asset Management L.P. owned 1.50% of enGene worth $4,376,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Wolverine Asset Management LLC bought a new stake in enGene in the 3rd quarter valued at $37,000. SR One Capital Management LP bought a new stake in enGene in the 2nd quarter valued at $4,715,000. Finally, Logos Global Management LP lifted its position in enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company's stock valued at $11,316,000 after acquiring an additional 400,000 shares in the last quarter. 64.16% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Raymond James assumed coverage on shares of enGene in a research report on Wednesday, November 27th. They set an "outperform" rating and a $23.00 price target on the stock. Morgan Stanley reissued an "overweight" rating and set a $40.00 price target on shares of enGene in a research report on Wednesday, September 11th. Oppenheimer restated an "outperform" rating and set a $30.00 price objective on shares of enGene in a research note on Tuesday, September 24th. JMP Securities restated a "market outperform" rating and set a $18.00 price objective on shares of enGene in a research note on Friday. Finally, Citizens Jmp upgraded shares of enGene to a "strong-buy" rating in a research note on Monday, November 18th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $30.38.

enGene Price Performance

ENGN traded down $0.39 on Monday, reaching $8.26. The company had a trading volume of 21,416 shares, compared to its average volume of 115,653. enGene Holdings Inc. has a fifty-two week low of $4.42 and a fifty-two week high of $18.40. The company's fifty day moving average is $8.15 and its 200 day moving average is $8.08. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09.

enGene (NASDAQ:ENGN - Get Free Report) last announced its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.05. On average, analysts forecast that enGene Holdings Inc. will post -1.52 earnings per share for the current year.

Insider Activity at enGene

In other news, CEO Ronald Harold Wilfred Cooper purchased 10,000 shares of the business's stock in a transaction dated Friday, September 27th. The stock was bought at an average price of $5.70 per share, with a total value of $57,000.00. Following the acquisition, the chief executive officer now owns 10,000 shares in the company, valued at approximately $57,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Growth Opportunities F. Forbion purchased 41,639 shares of the business's stock in a transaction dated Friday, September 27th. The shares were purchased at an average cost of $5.97 per share, with a total value of $248,584.83. Following the acquisition, the insider now owns 2,059,459 shares in the company, valued at $12,294,970.23. This trade represents a 2.06 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 420,965 shares of company stock worth $2,651,103. Insiders own 13.70% of the company's stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.